A detailed history of Y Intercept (Hong Kong) LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Y Intercept (Hong Kong) LTD holds 46,167 shares of BMY stock, worth $2.31 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
46,167
Holding current value
$2.31 Million
% of portfolio
0.11%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $1.86 Million - $2.45 Million
46,167 New
46,167 $1.92 Million
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $916,126 - $1.09 Million
18,897 Added 145.15%
31,916 $1.64 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $4.26 Million - $4.76 Million
-73,577 Reduced 84.97%
13,019 $755,000
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $5.52 Million - $6.13 Million
86,596 New
86,596 $5.54 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $675,692 - $800,115
9,867 Added 19.38%
60,782 $4.37 Million
Q2 2022

Aug 08, 2022

BUY
$72.62 - $79.98 $2.32 Million - $2.56 Million
32,009 Added 169.31%
50,915 $3.92 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $1.16 Million - $1.39 Million
18,906 New
18,906 $1.38 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $794,474 - $926,171
-14,814 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $341,292 - $399,780
-5,768 Reduced 28.02%
14,814 $877,000
Q2 2021

Aug 26, 2021

BUY
$61.91 - $67.42 $1.27 Million - $1.39 Million
20,582 New
20,582 $1.38 Million
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $979,292 - $1.07 Million
-15,818 Closed
0 $1.38 Million
Q1 2021

May 12, 2021

BUY
$59.34 - $66.74 $611,795 - $688,089
10,310 Added 187.18%
15,818 $1 Million
Q4 2020

Feb 05, 2021

BUY
$57.74 - $65.43 $318,031 - $360,388
5,508 New
5,508 $341,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $107B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Y Intercept (Hong Kong) LTD Portfolio

Follow Y Intercept (Hong Kong) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.